title: Phase II Study of Dasatinib in Previously Treated Patients with Advanced Non-Small Cell Lung Cancer.
abstract: The Src pathway in activated in about one-third of non-small cell lung cancer (NSCLC) tumors. Dasatinib has Src-inhibitor activity. We examined the activity of dasatinib in 37 patients with advanced, previously treated NSCLC. Among the 29 patients who underwent pre-treatment biopsy for RNA biomarker analysis, 25 were treated with dasatinib 70 mg twice daily. There were no responses. Five patients discontinued treatment due to toxicity. Three patients had minor biopsy-related pneumothoraces. Given the lack of responses, no biomarkers were analyzed. Dasatinib 70 mg twice daily does not have activity nor is it well tolerated in unselected patients with advanced stage, previously treated NSCLC.
authors.affiliation: a Division of Medical Oncology, Department of Medicine , Duke University Medical Center , Durham , North Carolina , USA.|b Duke Cancer Institute, Duke University Medical Center , Durham , North Carolina , USA.|c Medical Service , Durham Veterans Affairs Medical Center , Durham , North Carolina , USA.
authors.forename: Michael J
authors.initials: MJ
authors.lastname: Kelley
authors.affiliation: d Division of Hematology, Oncology, and Transplantation, Department of Medicine , University of Minnesota , Minneapolis , Minnesota , USA.
authors.forename: Gautam
authors.initials: G
authors.lastname: Jha
authors.affiliation: b Duke Cancer Institute, Duke University Medical Center , Durham , North Carolina , USA.
authors.forename: Debra
authors.initials: D
authors.lastname: Shoemaker
authors.affiliation: b Duke Cancer Institute, Duke University Medical Center , Durham , North Carolina , USA.
authors.forename: James E
authors.initials: JE
authors.lastname: Herndon
authors.affiliation: b Duke Cancer Institute, Duke University Medical Center , Durham , North Carolina , USA.
authors.forename: Lin
authors.initials: L
authors.lastname: Gu
authors.affiliation: b Duke Cancer Institute, Duke University Medical Center , Durham , North Carolina , USA.|e Department of Biostatistics and Computational Biology , Dana-Farber Cancer Institute , Boston , Massachusetts , USA.
authors.forename: William T
authors.initials: WT
authors.lastname: Barry
authors.affiliation: a Division of Medical Oncology, Department of Medicine , Duke University Medical Center , Durham , North Carolina , USA.|b Duke Cancer Institute, Duke University Medical Center , Durham , North Carolina , USA.
authors.forename: Jeffrey
authors.initials: J
authors.lastname: Crawford
authors.affiliation: a Division of Medical Oncology, Department of Medicine , Duke University Medical Center , Durham , North Carolina , USA.|b Duke Cancer Institute, Duke University Medical Center , Durham , North Carolina , USA.
authors.forename: Neal
authors.initials: N
authors.lastname: Ready
mesh_terms: D000284:Administration, Oral; D000368:Aged; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy* / Q000235:genetics; D000069439:Dasatinib / Q000008:administration & dosage* / Q000009:adverse effects / Q000627:therapeutic use; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000235:genetics; D008297:Male; D008875:Middle Aged; D047428:Protein Kinase Inhibitors / Q000008:administration & dosage* / Q000009:adverse effects / Q000627:therapeutic use; D017211:Treatment Failure; D016896:Treatment Outcome; D019061:src-Family Kinases / Q000037:antagonists & inhibitors
chemical_list: D047428:Protein Kinase Inhibitors; D019061:src-Family Kinases; D000069439:Dasatinib
keywords: Non-small cell lung cancer; Src; gene expression